source
- Silence brings the noise to Takeda with phase 2 blood cancer winA phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…Fierce Biotech · 19h ago↗ source
- BlossomHill and Latigo Biotherapeutics raise over 30% beyond IPO targetsTwo emerging biotech companies surpassed their initial public offering expectations on Friday, with both BlossomHill Therapeutics and Latigo Biotherapeutics raising at least 30% more capital than p…